-transparent.png){kind=logo}
The pharmacokinetics of a potentially useful antitumor agent, 2,4-diamino-5-adamantyl-6-methylpyrimidine (DAMP) has been studied in rat using 14C-labeled drug. It is reported that DAMP is metabolized rapidly by liver microsomes to an unidentified compound. The metabolite seems to be excreted by liver more rapidly than the unchanged drug, and within 24 hours all radioactivity is eliminated, 80% through kidney and 20% through the bile. Both DAMP, and its metabolite accumulate readily in pancreas and kidney. In contrast, in the brain mostly unchanged DAMP could be detected. The accumulation of the drug in tissues other than liver is much greater after i.v. than after i.p. administration.
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
June 1982,
Cancer research,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
January 1983,
Cancer biochemistry biophysics,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
January 1988,
Cancer chemotherapy and pharmacology,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
June 1980,
Cancer treatment reviews,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
January 1980,
European journal of cancer,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
May 1951,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
July 1977,
Journal of chromatography,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
July 1981,
Journal of pharmaceutical sciences,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
December 1977,
Journal of clinical pathology,
S F Zakrzewski, and
C Dave, and
L H Mead, and
D S Deluomo
May 1991,
Anti-cancer drug design,
